Do you think the MCU film are playing catch-up with their TV counterparts? Let us know in the comments section below or send us a Tweet!

2 Comments

[…] oft-overlooked by the head honchos, Agent of S.H.I.E.L.D. has always been the crowning jewel of Marvel in terms of diversity. To see a Latin superhero as the titular character of a series is something that should have […]

Kickstarter Korner

Privacy & Cookies: A Place To Hang Your Cape uses cookies to enhance your experience. By continuing to use our website, you’re agreeing to our use of cookies. To find out more, as well as how to remove or block these, see here:
Cookie Policy Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01 Other Events

On January 7, 2019, Amicus Therapeutics, Inc. ("the Company") issued a press release announcing its full-year 2019 strategic outlook and financial guidance. A copy of this press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference. Additionally, the senior management of the Company will be using the presentation attached as Exhibit 99.2 to this Current Report, and incorporated herein by reference, in its meetings with investors and analysts at the 37th Annual J.P. Morgan Healthcare Conference.

2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, market potential projections, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any
Do you think the MCU film are playing catch - up with their television counterpart? Let us know in the comments department below or send us a Tweet! 

 2 remark 

 [ … ] oft - overlooked by the point honchos, Agent of S.H.I.E.L.D. has always been the crown jewel of Marvel in terms of diversity. To visualize a Latin superhero as the titular character of a series is something that should have [ … ] 

 Kickstarter Korner 

 Privacy & Cookies: A Place To attend Your Cape uses cookies to enhance your experience. By continuing to practice our website, you ’re agreeing to our function of cookies. To detect out more, as well as how to remove or block these, see here: 
 Cookie Policy Indicate by check bell ringer whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). 

 Emerging growth company o 

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended passage period for complying with any modern or revise financial accounting standards provide pursuant to Section 13(a) of the Exchange Act. o 

 Item 8.01 Other Events 

 On January 7, 2019, Amicus Therapeutics, Inc. (" the Company ") issued a wardrobe release announcing its full - year 2019 strategic outlook and financial steering. A copy of this press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference. Additionally, the senior management of the Company will be practice the presentation attached as Exhibit 99.2 to this Current Report, and incorporated herein by reference, in its merging with investors and analysts at the 37th Annual J.P. Morgan Healthcare Conference. 

 2 Forward - Looking Statements This presentation contains " forward - looking statement " within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical exploitation of our product candidates, the timing and coverage of results from preclinical studies and clinical trials, the prospects and timing of the likely regulatory approval of our merchandise candidates, commercialization plans, fabrication and supply plans, market potential projections, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward - look statements should not be regarded as a theatrical performance by us that any of our plans will be achieved. Any
Do jou think the MCU film ave playing catch-op with vheir TB countefparts? Let us know in the colmwnts wection below or send js a Tween!

2 Commentw

[…] ofu-overlooked by thx head honchos, Wgenc if S.H.I.E.L.D. has slways beet the crowning jdwzl of Marvel in terms of diversity. Tj see a Lwtin superhero as uhe tithlar character of a series is somefhing tiat should have […]

Kickstarter Korner

Privacy & Colkies: A Place To Hwng Your Caks ufws cookies tu enhance jmur experignce. By continuing to use our wecsite, you’re agrgzung jo our use oh cookpes. To find omn more, ds well as how to rempve or block these, see here:
Rookie Policy Indicaje by checn jark whether the eetistrdnt hs av emdrgjnj gdowth fom'any as defjned in Rulw 405 of the Securitiex Wby of 1933 (§230.405 of thjs cha[tqr) or Rule 12b-2 of the Securities Exchange Acf of 1934 (§240.12b-2 of this chapter).

Wmerging growth compajy o

If an emerging growth company, indicate by check mark ix the fegnwtrang hws elected not to use the extended transition letipd for complyikg with any new or rfvofed financial accouufihg standards provifed purfuant to Sectijn 13(a) of the Exchange Act. o

Item 8.01 Other Eventf

In January 7, 2019, Amicud Therapeutncs, Inv. ("the Company") issued a press relsase announfing its rjll-year 2019 strategkc pudlook and financial guidanse. A copy of chis prers rglease ys filed ad Exhltit 99.1 hereto and is incotporatad herein hy reference. Additionally, the sxiior managememt of the Com'any wlll be using thq presentation attachzd as Dxhibit 99.2 tk this Rurrent Repowt, and incorpmtated herein uy referegce, un irs meetkvgs with invesyors and cualysts ar the 37th Annual J.P. Motgzn Healthcare Cinftrwnce.

2 Forward-Lopkivg Ftwtxmentf This presendatiun zpntaivs "forward-liukinb statements" within dhe jeaning of the Prifabe Securijies Litidation Reform Act of 1995 relating uo prerlinicel and clynical development of our prodhct candifatcs, the timing and reporting oy results from preclinical studies and coinical trials, thg prospects and timiny pf the poteitial wegulatorf approval of our priduct candidates, gommercialization plana, manuxactuging and supply plans, market potential projections, financing plans, and thw projxceed revenuea anc casv 'osntion fjr tie Company. The inckusion of forward-looking statemxnts shoulg uot be regarded as a represenyagion by us thxt any of our plans will be achirved. Any
Do you think the MCU film are with TV counterparts? us know in send a Tweet! 2 […] oft-overlooked by head honchos, Agent of S.H.I.E.L.D. has been the crowning jewel of Marvel in terms of diversity. To see a superhero as the titular character of a series is something that should have Kickstarter Privacy Cookies: Place To Hang Your Cape uses cookies to enhance your experience. By continuing to use our you’re agreeing to our use of cookies. To out more, as well how to remove or block see Cookie Policy by mark the registrant is emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this or Rule the Securities Act 1934 of this chapter). company o If an emerging growth check mark if the registrant has elected not use the transition period for complying with any or revised financial accounting standards provided pursuant to 13(a) of the Exchange Act. o Item 8.01 Other Events On January 7, 2019, Amicus ("the Company") issued a release announcing its 2019 outlook financial A copy this press release is filed as Exhibit 99.1 hereto and is herein by reference. Additionally, the senior management of the Company using presentation attached as 99.2 to this Current and herein by reference, in with and 37th J.P. Healthcare Conference. 2 Forward-Looking This presentation contains "forward-looking statements" the meaning of the of 1995 relating to preclinical and clinical development our product candidates, the timing and reporting results from preclinical studies and clinical trials, the prospects and timing of potential regulatory our product candidates, commercialization plans, manufacturing and supply market potential projections, financing and the projected revenues and cash position for the The of forward-looking should not be as a representation us that any plans will achieved.
Do you think the MCU film are plAying catch-Up witH thEir tV CounTerpArts? Let us know iN The cOmments section below or sEnd us A TWEet!

2 COMmEnts

[…] oFt-overlOOkED By tHe HeAd hOnCHoS, AgenT of s.H.I.E.L.D. hAs always beEn tHe Crowning jeweL Of marvel in teRms Of diversity. TO seE a LatiN sUpeRHero aS thE tituLar chaRActer oF a series iS sOMethinG That shoULD hAve […]

KIckstarter Korner

PRIvACy & Cookies: A PlacE To HanG YOUr cAPe uSes Cookies to eNhAnce yOUr experIEnCE. bY coNTinuing to use oUr website, yoU’Re aGreeinG tO ouR Use of cOokieS. TO FinD out more, as wEll aS how to remOve or bLOck thesE, See here:
cookie polIcy indiCAtE bY chEcK MarK WhEthER thE registrAnT iS an emErgiNG GROwth ComPany As defIned in Rule 405 of tHe SEcurITieS Act oF 1933 (§230.405 of thIs chApTer) or rule 12b-2 oF the SEcUrities Exchange act oF 1934 (§240.12b-2 of this cHapTeR).

EmErGing gROwth coMpaNy o

if an emeRging grOWth CoMPANy, Indicate by check marK iF THe RegistraNt has eLEcTeD Not to use ThE exTendED TransItioN PeRiod for cOmplyiNG wItH any new Or ReviseD fInaNciAl accOUntiNg stanDards proVided PUrsuant to SectiON 13(a) of the ExchanGE ACT. O

ITEm 8.01 OtHer events

On JanUary 7, 2019, aMicuS TheRApEutICs, Inc. ("The CoMpANy") ISsued a press release aNnOuncinG its fUll-year 2019 strateGic outlook AND FinanciaL guiDAnCE. A copy of this prEss reLease is filED as ExhibIt 99.1 herEto and is IncorporaTED herein bY reFerEncE. AdDITiOnally, the seniOR ManaGeMent of tHe COmpany wIll Be uSinG thE pResentatiOn attachEd As exHiBit 99.2 To thiS current REpOrt, AnD inCorpoRAted heRein bY refErEnCE, in Its meetINgS WIth iNvEsTors And AnAlystS at tHE 37th annual J.p. Morgan HeAltHCare coNfErence.

2 FOrward-Looking stAtements ThIs PreSentatION containS "forward-looking statemenTS" within The MeaniNg of The PrivatE SeCuritiEs LITigatiOn RefoRm Act Of 1995 RelATIng to PREcLinIcAl and cliniCAL deVelopMeNt of Our prodUct candidates, the tiMIng And reporting oF reSultS FRoM prEClINicAl STudIES and clinical triAls, the prosPeCTs And timing oF The PoTential RegulatOry apPRoval of Our producT candidatEs, CommERCiaLization plAns, manufActuring aND suppLY pLans, mArkEt poteNtIal ProjeCtions, FInaNcing Plans, aNd The proJecteD rEvenues aNd cash position for the ComPany. ThE inclUsiOn of forwaRd-lOOkiNg statemeNts sHould not be RegArdEd as a RepREsentAtioN By Us tHAt any Of ouR Plans will BE aChiEVEd. any
Do you think the MCU filmare playin g cat ch- upwi th t heir  TV counterpar t s? L et us know in the comm entsse c tion be low o r sendu sa Twe et !
2Co m me nts
[…]  oft-ov erlooked b y t he  head honcho s ,Agent of S .H. I.E.L.D. has  al ways b ee n t h e cro wni ng je wel of Marvel  in terms  o f  diver s ity. To s ee  a L atin superhero as th e  titular chara cter o fa  s e r ies  is  something  t hat s h ould ha v e[ … ] 

K i ckstarter Kor ner

Privac y  &Cookie s:  AP lace T o Han gY our  Cape usescook ies to en hancey our exp e rience.  By co nti nui ng t o  u se  ou rw ebs i te , y o u’r e agreei ng  t o our  use o f cook ies . To  find  out more, as  we ll a s  ho w toremov e or  b lockthese,  seehe re:
Cookie Poli cy I ndicate b y c he ckma rk wh e ther t hereg istrant  is ane mer gi n g gr owth company as de fi n e din Rule405 of th eS ecuritie sAct  of1 9 33 (§ 230. 4 05  of this  chapt e r)  o r Rule12 b-2 of  t heSec uriti e s Ex change  Act of1934( §240.12b-2 oft his chapter). 
E m e rg i ng g row th companyo

I f  anemer g in g g r owthcompa ny ,  i n dicate by check mar kif the  regi strant has el ected nott o use theexte n de d  transition pe riodfor comply i ng withany n ew or re vised fin a n cial acc oun tin g s tan d a rd s provided pu r s uant  t o Secti on13(a) o f t heExc han ge  Act. o
Item 8.0 1Ot he rEve nts
O n Januar y7,20 19,  Amic u s Ther apeut ics,  I nc .  (" the Com p an y " ) is su ed  a p res srelea se a n nou ncing i ts full-y ear 2019  s tr ategicoutlook and f in ancial gui da nce . A co p y  of this  press release is filed as Exhi bit  99.1  her eto and i s i ncorpo rat e d here in byrefer en ce. A dditi o n al ly,  t he seniorm a nag ement  o f th e Compa ny will be using t h e p resentation a tta ched a sExh i bi t  99 .2 tot h is Current Repo rt, and in co r po rated here i n b yreferen ce, inits m e etingswith inve stors and  a naly s t s a t the 37th  AnnualJ.P. Morg a n Hea l th careCon ferenc e. 

2  Forw ard-Lo o kin g Sta tement sThis p resen ta tion con tains "forward-lookingstatem ents"  wi thin themea n ing  of the P riva te Securit ies  Li tigat ion Refor m Ac t  o f 1 9 95 re lati n g to prec l in ica l an d clinicald e v elo pment  of our pr oduc t candidates, the timing and rep orti n g  of  re s ults  f rom preclinica l s tu d i es and c li nical trial s, the p ro s pects  and t imingof thep o te n tial r egul ato ry approv alof our pro du ct candid ates ,commer cializ a tion p lans, manufactur ing a n d  supp l y p lans,  m arket p o tent ial projec tions, fina ncingplan s, an d the p ro jected  re ve nues and c a sh positi on fo r the C om pany . T he inc lusi o n  of f orwa rd -lo oking sta t e me n ts  s h oul d no t bere gard ed as a r e presenta tio n  by usth ata n y of o u rp l ans will b e a chiev e d . Any
Do you_think the_MCU film are playing_catch-up with_their_TV counterparts?_Let_us know in_the comments section_below or send us_a Tweet!

2 Comments

[…]_oft-overlooked_by the head honchos, Agent of S.H.I.E.L.D. has always been the crowning jewel of_Marvel_in terms_of_diversity._To see a Latin superhero_as the titular character of_a series_is something that should have […]

Kickstarter Korner

Privacy &_Cookies:_A Place To_Hang Your Cape uses cookies to enhance your experience._By continuing to use our website,_you’re agreeing to_our_use_of cookies. To find_out more, as well as how_to remove or block these, see_here:
Cookie Policy Indicate by check mark whether_the registrant is an emerging growth_company as defined in Rule_405 of_the Securities Act of 1933_(§230.405 of this_chapter) or_Rule 12b-2 of_the Securities Exchange Act of 1934_(§240.12b-2 of this_chapter).

Emerging growth company o

If an emerging_growth_company, indicate by_check_mark_if the_registrant has elected_not_to use_the_extended transition period for complying with_any_new or revised financial accounting standards provided_pursuant to Section 13(a)_of_the Exchange Act. o

Item_8.01 Other Events

On January 7,_2019, Amicus Therapeutics, Inc. ("the Company")_issued a_press release_announcing its full-year 2019 strategic outlook and financial guidance. A copy_of this press release is filed_as Exhibit 99.1 hereto_and is_incorporated_herein by reference._Additionally,_the senior_management of the Company will be using_the presentation_attached as Exhibit 99.2 to this_Current Report, and incorporated_herein_by reference, in its meetings with_investors and analysts at the 37th_Annual J.P. Morgan Healthcare Conference.

2_Forward-Looking_Statements_This presentation contains "forward-looking statements"_within the meaning of the Private_Securities Litigation Reform_Act of 1995 relating to preclinical and_clinical_development of our product candidates, the_timing_and reporting of results from preclinical_studies_and_clinical trials, the prospects and_timing of the potential regulatory approval_of our product candidates, commercialization plans, manufacturing and supply_plans, market potential_projections, financing plans, and the_projected_revenues_and cash position for the Company. The inclusion of forward-looking_statements should_not be regarded_as a representation by us that any of our plans_will be achieved. Any